| NCT ID | NCT05733806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Naples |
| Condition | Gynecologic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-10-14 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2019-10-14 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, observational, multicenter study on gynecological rare tumors.
Eligibility Criteria
Inclusion Criteria: * rare gynecological malignancies * written informed consent * patient fit for follow-up Exclusion criteria -written informed consent not provided
Contact & Investigator
Francesco Perrone, MD
PRINCIPAL INVESTIGATOR
IRCCS Fondazione G Pascale, Naples
Frequently Asked Questions
Who can join the NCT05733806 clinical trial?
This trial is open to female participants only, studying Gynecologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05733806 currently recruiting?
Yes, NCT05733806 is actively recruiting participants. Contact the research team at f.perrone@istitutotumori.na.it for enrollment information.
Where is the NCT05733806 trial being conducted?
This trial is being conducted at Milan, Italy, Naples, Italy.
Who is sponsoring the NCT05733806 clinical trial?
NCT05733806 is sponsored by National Cancer Institute, Naples. The principal investigator is Francesco Perrone, MD at IRCCS Fondazione G Pascale, Naples. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.